Many patients with major depressive disorder (MDD) do not improve or partially respond to
conventional antidepressant therapy. Therefore, augmentation therapy is required in many …

Depression is a potentially life-threatening disease that is one of the leading causes of
disability in the world. In 2017, more than 300 million people suffered from depression. That …

DISCUSSION To my knowledge, this is the first report of an “aripiprazole discontinuation
syndrome,” characterized by anxiety and restlessness without psychomotor findings …

Conclusion Cette étude de cohorte montre que les patients de 25 à 64 ans présentant une
dépression sévère, résistante après 3 mois de traitement par un premier antidépresseur …

Major Depressive Disorder (MDD) is one of the most common disorders in the US and
affects an estimated 17.3 million adults with its prevalence being higher among females …

Tikslai. Nepaisant prieinamų gydymui atsparios depresijos (GAD) gydymo galimybių,
įrodymais pagrįstų ir efektyvių gydymo galimybių skaičius šiai sunkiai gydomai populiacijai …

Achtergrond Hoewel antidepressiva de eerste keuze medicamenteuze behandeling zijn bij
ernstige depressie, is slechts 50% van de patiënten na een eerste behandeling met een …

This Commentary presents highlights of the roundtable meeting “Inadequate Response to
Antidepressant Treatment in Major Depressive Disorder,” which was held October 5, 2019 …

Objective Ketamine, an N-methyl D-aspartate (NMDA) receptor antagonist, can promote
rapid action in the management of individuals with treatment-resistant depression (TRD) at …

More than half a century after the discovery of the first antidepressant drug, the drug
treatment of depressive disorders is still a major problem, due to the high interindividual …